Navigation Links
Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model
Date:4/22/2009

-Preclinical Results Further Validate Significant Anti-Tumor Potential of Fully Human Anti-PS Antibodies and Expand the Company's PS-Targeting Platform-

-Treatment with Mouse Equivalent to the Human Antibody Inhibited Tumor Growth in a Prostate Cancer Model by More than 90%-

DENVER and TUSTIN, Calif., April 22 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today announced that preclinical data presented during the AACR 100th Annual Meeting 2009 shows that one of its fully human phosphatidylserine (PS)-targeting antibodies demonstrated encouraging signs of efficacy in a preclinical model of prostate cancer. These positive new data validate the anti-tumor potential of this human anti-PS antibody, which is similar to Peregrine's lead clinical stage antibody bavituximab and extends Peregrine's anti-PS antibody pipeline. Bavituximab is in Phase II clinical trials for the treatment of advanced breast cancer and non-small cell lung cancer.

Peregrine's PS-targeting antibodies bind to the cellular membrane component PS that is usually located inside cells, but which becomes exposed on the external surface of the cells that line the blood vessels of tumors (the tumor vascular endothelium), creating a specific target for anti-cancer treatments. By binding to PS, the antibodies are believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels.

In today's presentation, researchers from UT Southwestern Medical Center in Dallas and Affitech A/S reported that similar to bavituximab, the human antibody PGN635 targets and binds specifically to the tumor vascular endothelium(1). Treatment with androgen deprivation therapy or docetaxel substantially increased the percentage
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014   Reproductive Medicine Associates of ... the field of infertility, presents new clinical research ... The research abstract, released during the 70 th ... meeting in Honolulu, Hawaii , ... defect (SGD) pre-implantation genetic diagnosis (PGD). ...
(Date:10/22/2014)... , Oct. 22, 2014  CryoLife, Inc. (NYSE: ... processing company focused on cardiac and vascular surgery, announced ... and Chief Executive Officer, has been elected to the ... Steven G. Anderson , Executive Chairman of ... proven to be an excellent leader who is well ...
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the second fiscal quarter ended September ... Revenues of $53.9 million, up 18% over last year,s ... 33% over last year,s comparable quarter. Revenues ... Laboratories (AVRL) of $3.5 million, up 50% over last ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 Lintelus, ... Cormier, Sr. Vice President of Sales, will be speaking ... upcoming Meetings Technology Expo on October 28, at the ... be hosting a booth as well as a Tech ... Lintelus Meeting can create a more engaging event experience. ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... undergoing in vitro fertilization (IVF) are only about half as ... assisted reproduction technique, new research indicates, and the racial disparity ... study, about 31 percent of white patients became pregnant after ... Analyzing more than 4,000 IVF cycles over two years to ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Measures taken by Firestone ... Ebola-ravaged Liberia may have limited the spread of the ... The Firestone Natural Rubber Co. provides health services ... of nearby densely populated communities. Between Aug. 1 ... Ebola cases among those 80,000 people. That incidence rate ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... proteins found in blood serum shows promise as a sensitive ... Southwestern Medical Center have found as part of a statewide ... clinical exam, proved 94 percent accurate in detecting suspected Alzheimer,s ... without the disease, the researchers said. "This research ...
... HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay ... for injury-related emergency room visits in the United States ... has been a dramatic increase in the likelihood of ... emergency departments for injury-related conditions without a corresponding increase ...
... awarded a three-year, $2.6-million grant to the University ... Therapeutics, Inc., to establish dosing and safety guidelines ... into animal models of Alzheimer,s disease. The researchers ... U.S. Food and Drug Administration approval to carry ...
... White Cancer Center,s Breast Cancer Clinic program has earned ... Program for Breast Centers (NAPBC), a program administered by ... White breast cancer is managed by a team, and ... care," said Christopher O. Ruud, M.D., director of the ...
... microscope in a major new study, led by an academic ... potential advantages and disadvantages. The study, which is funded ... the motives people have for travelling across national boundaries to ... or joint replacement, cosmetic surgery and fertility treatment. Dr ...
... , TUESDAY, Oct. 5 (HealthDay News) -- Older women who ... suffer from heart disease than those who don,t, new findings ... improves the heart health of women by lowering the risk ... seemed to have no benefit for men at all in ...
Cached Medicine News:Health News:Blood test could diagnose Alzheimer's disease, UT Southwestern researchers find 2Health News:MRI, CT Scans for ER Patients Triple Over Decade 2Health News:MRI, CT Scans for ER Patients Triple Over Decade 3Health News:USF and Saneron get $2.6 million to develop Alzheimer's treatment using umbilical cord blood cells 2Health News:Scott & White breast cancer program receives accreditation 2Health News:Traveling for treatment: The case for and against 2Health News:Dental Care Linked to Heart Health in Older Women 2
Inquire...
... Implants come in three styles. Each style ... far the most popular style. Pectoral Implants ... packaged and sold individually, not in pairs. ... are each made for a specific side ...
... in the IQmark family elevates your ECG and ... portability, cost-savings and efficient patient care. The IQmark ... the office, clinics and medical centers as well ... used in conjunction with the IQmark Digital ECG ...
... Holter is engineered to set a new ... do is enter the patient demographics, select ... three-channel, Windows based system uses the latest ... and versatility of the IQmark Holter algorithm. ...
Medicine Products: